These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
157 related articles for article (PubMed ID: 22241894)
21. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy. Jacobsen P; Andersen S; Jensen BR; Parving HH J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333 [TBL] [Abstract][Full Text] [Related]
22. Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade. Mifsud SA; Allen TJ; Bertram JF; Hulthen UL; Kelly DJ; Cooper ME; Wilkinson-Berka JL; Gilbert RE Diabetologia; 2001 Jul; 44(7):878-82. PubMed ID: 11508273 [TBL] [Abstract][Full Text] [Related]
23. Angiotensin-receptor blockers: revival of the systemic prevention of restenosis? Wilensky RL Cardiovasc Drugs Ther; 2003 Jan; 17(1):63-73. PubMed ID: 12843688 [TBL] [Abstract][Full Text] [Related]
25. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. Pfeffer MA; McMurray JJ; Velazquez EJ; Rouleau JL; Køber L; Maggioni AP; Solomon SD; Swedberg K; Van de Werf F; White H; Leimberger JD; Henis M; Edwards S; Zelenkofske S; Sellers MA; Califf RM; N Engl J Med; 2003 Nov; 349(20):1893-906. PubMed ID: 14610160 [TBL] [Abstract][Full Text] [Related]
26. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. VAL-K Study Group. Bakris GL; Siomos M; Richardson D; Janssen I; Bolton WK; Hebert L; Agarwal R; Catanzaro D Kidney Int; 2000 Nov; 58(5):2084-92. PubMed ID: 11044229 [TBL] [Abstract][Full Text] [Related]
27. Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease. Martin J; Krum H Pharmacol Res; 2002 Sep; 46(3):203-12. PubMed ID: 12220962 [TBL] [Abstract][Full Text] [Related]
28. Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies. Allen TJ; Cao Z; Youssef S; Hulthen UL; Cooper ME Diabetes; 1997 Oct; 46(10):1612-8. PubMed ID: 9313758 [TBL] [Abstract][Full Text] [Related]
29. [Effects of long term therapy with angiotensin converting enzyme inhibitor quinapril, antagonist of receptors to angiotensin II valsartan, and combination of quinapril and valsartan in patients with moderate chronic heart failure. Main results of the SADKO-CHF study]. Skvortsov AA; Nasonova SN; Sychev AV; Orlova IaA; Baklanova NA; Masenko VP; Mareev VIu; Belenkov IuN Kardiologiia; 2006; 46(7):33-51. PubMed ID: 16883264 [TBL] [Abstract][Full Text] [Related]
30. Augmented short- and long-term hemodynamic and hormonal effects of an angiotensin receptor blocker added to angiotensin converting enzyme inhibitor therapy in patients with heart failure. Vasodilator Heart Failure Trial (V-HeFT) Study Group. Baruch L; Anand I; Cohen IS; Ziesche S; Judd D; Cohn JN Circulation; 1999 May; 99(20):2658-64. PubMed ID: 10338459 [TBL] [Abstract][Full Text] [Related]
31. Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice. McMurray J; Cohen-Solal A; Dietz R; Eichhorn E; Erhardt L; Hobbs FD; Krum H; Maggioni A; McKelvie RS; Piña IL; Soler-Soler J; Swedberg K Eur J Heart Fail; 2005 Aug; 7(5):710-21. PubMed ID: 16087129 [TBL] [Abstract][Full Text] [Related]
32. Valsartan and recurrent atrial fibrillation. Tomoda H N Engl J Med; 2009 Jul; 361(5):532-3; author reply 533. PubMed ID: 19645082 [No Abstract] [Full Text] [Related]
33. Maximally recommended doses of angiotensin-converting enzyme (ACE) inhibitors do not completely prevent ACE-mediated formation of angiotensin II in chronic heart failure. Jorde UP; Ennezat PV; Lisker J; Suryadevara V; Infeld J; Cukon S; Hammer A; Sonnenblick EH; Le Jemtel TH Circulation; 2000 Feb; 101(8):844-6. PubMed ID: 10694521 [TBL] [Abstract][Full Text] [Related]
34. Effect of indomethacin on the antihypertensive efficacy of valsartan and lisinopril: a multicentre study. Fogari R; Zoppi A; Carretta R; Veglio F; Salvetti A; J Hypertens; 2002 May; 20(5):1007-14. PubMed ID: 12011663 [TBL] [Abstract][Full Text] [Related]
35. Angiotensin II receptor antagonists in chronic heart failure: where do they fit? Houghton AR Drugs; 2002; 62(10):1433-40. PubMed ID: 12093312 [TBL] [Abstract][Full Text] [Related]
36. [Info-congress. COPERNICUS and Val-HEFT studies]. Kulbertus H Rev Med Liege; 2000 Nov; 55(11):1018-20. PubMed ID: 11195705 [No Abstract] [Full Text] [Related]
37. Valsartan in acute myocardial infarction trial (VALIANT): rationale and design. Pfeffer MA; McMurray J; Leizorovicz A; Maggioni AP; Rouleau JL; Van De Werf F; Henis M; Neuhart E; Gallo P; Edwards S; Sellers MA; Velazquez E; Califf R Am Heart J; 2000 Nov; 140(5):727-50. PubMed ID: 11054617 [TBL] [Abstract][Full Text] [Related]
38. Cardiac angiotensin is upregulated in the hearts of unstable angina patients. Luft FC Circ Res; 2004 Jun; 94(12):1530-2. PubMed ID: 15217917 [No Abstract] [Full Text] [Related]
39. Valsartan in chronic heart failure. Campbell DJ N Engl J Med; 2002 Apr; 346(15):1173-4. PubMed ID: 11951863 [No Abstract] [Full Text] [Related]